title: Helicobacter pylori eradication in renal recipient: triple or quadruple therapy?
abstract: Although triple (omeprazole, amoxicillin, and metronidazole) and quadruple (omeprazole, tetracycline, metronidazole, and bismuth subcitrate) therapeutic regimens for H. pylori eradication has been studied much in the general population, there is a lack of data in renal transplanted patients. So, this study aimed at comparing regimens in these patients who were considered being immunocompromised. The present clinical trial was carried out in Mashhad, Iran in 2010. Fifty-five patients who had received a kidney transplant in six months or earlier and referred for chronic dyspepsia were selected. They were resistant to H2-receptor antagonists or proton pump inhibitors therapy and had positive Rapid ‎Urea Test. They randomly divided into two groups: triple and quadruple therapy. The treatment duration in both groups was similar (antibiotics for two weeks plus omeprazole for 4 weeks). Urea Breath Test (UBT) was performed two weeks after treatment for assessment of its result. Total numbers of 39 patients (71%) were positive for H. Pylori which were divided into triple therapy group (21 patients) and quadruple therapy (18 patients). Overall, the treatment was successful in 80% (71% in triple therapy and 89% in quadruple one) which was not different significantly between the groups (p=0.247). The result of this study revealed that the prevalence of H. pylori infection in renal transplant patients is similar to the normal population. In these cases, triple and quadruple therapies were similar in eradication of H. pylori. So, triple therapy can be recommended in renal transplant recipients.
authors.affiliation: Department of Gastrology, Ghaem Hospital, Mashhad, Iran hoseinimr@mums.ac.ir.
authors.forename: Seyed Mousal Reza
authors.initials: SM
authors.lastname: Hosseini
authors.affiliation: Department of Nephrology, Emam Reza Hospital, Mashhad, Iran sharifipourf@mums.ac.ir.
authors.forename: Farzane
authors.initials: F
authors.lastname: Sharifipoor
authors.affiliation: Department of Nephrology, Emam Reza Hospital, Mashhad, Iran nazemianf@mums.ac.ir.
authors.forename: Fateme
authors.initials: F
authors.lastname: Nazemian
authors.affiliation: Department of Gastrology, Ghaem Hospital, Mashhad, Iran my_nadia2000@yahoo.com.
authors.forename: Hossein
authors.initials: H
authors.lastname: Ghanei
authors.affiliation: Department of Gastrology, Ali-Ibne Abitaleb Hospital, Zahedan, Iran hamidreza.zivarifar@hotmail.com.
authors.forename: Hamid Reza
authors.initials: HR
authors.lastname: Zivarifar
authors.affiliation: Department of Gastrology, Vali-e-Asr Hospital, Birjand, Iran fakhariant891@mums.ac.ir.
authors.forename: Tahereh
authors.initials: T
authors.lastname: Fakharian
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001944:Breath Tests; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D016867:Immunocompromised Host; D007492:Iran; D016030:Kidney Transplantation; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D009942:Organometallic Compounds; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D000658:Amoxicillin; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole